Literature DB >> 26182988

Viral delivery of shRNA to amygdala neurons leads to neurotoxicity and deficits in Pavlovian fear conditioning.

Christopher A de Solis1, Roopashri Holehonnur1, Anwesha Banerjee1, Jonathan A Luong1, Srihari K Lella1, Anthony Ho1, Bahram Pahlavan1, Jonathan E Ploski2.   

Abstract

The use of viral vector technology to deliver short hairpin RNAs (shRNAs) to cells of the nervous system of many model organisms has been widely utilized by neuroscientists to study the influence of genes on behavior. However, there have been numerous reports that delivering shRNAs to the nervous system can lead to neurotoxicity. Here we report the results of a series of experiments where adeno-associated viruses (AAV), that were engineered to express shRNAs designed to target known plasticity associated genes (i.e. Arc, Egr1 and GluN2A) or control shRNAs that were designed not to target any rat gene product for depletion, were delivered to the rat basal and lateral nuclei of the amygdala (BLA), and auditory Pavlovian fear conditioning was examined. In our first set of experiments we found that animals that received AAV (3.16E13-1E13 GC/mL; 1 μl/side), designed to knockdown Arc (shArc), or control shRNAs targeting either luciferase (shLuc), or nothing (shCntrl), exhibited impaired fear conditioning compared to animals that received viruses that did not express shRNAs. Notably, animals that received shArc did not exhibit differences in fear conditioning compared to animals that received control shRNAs despite gene knockdown of Arc. Viruses designed to harbor shRNAs did not induce obvious morphological changes to the cells/tissue of the BLA at any dose of virus tested, but at the highest dose of shRNA virus examined (3.16E13 GC/mL; 1 μl/side), a significant increase in microglia activation occurred as measured by an increase in IBA1 immunoreactivity. In our final set of experiments we infused viruses into the BLA at a titer of (1.60E+12 GC/mL; 1 μl/side), designed to express shArc, shLuc, shCntrl or shRNAs designed to target Egr1 (shEgr1), or GluN2A (shGluN2A), or no shRNA, and found that all groups exhibited impaired fear conditioning compared to the group which received a virus that did not express an shRNA. The shEgr1 and shGluN2A groups exhibited gene knockdown of Egr1 and GluN2A compared to the other groups examined respectively, but Arc was not knocked down in the shArc group under these conditions. Differences in fear conditioning among the shLuc, shCntrl, shArc and shEgr1 groups were not detected under these circumstances; however, the shGluN2A group exhibited significantly impaired fear conditioning compared to most of the groups, indicating that gene specific deficits in fear conditioning could be observed utilizing viral mediated delivery of shRNA. Collectively, these data indicate that viral mediated shRNA expression was toxic to neurons in vivo, under all viral titers examined and this toxicity in some cases may be masking gene specific changes in learning. Therefore, the use of this technology in behavioral neuroscience warrants a heightened level of careful consideration and potential methods to alleviate shRNA induced toxicity are discussed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV; Amygdala; Fear conditioning; RNA interference; Viral; shRNA

Mesh:

Substances:

Year:  2015        PMID: 26182988      PMCID: PMC4568141          DOI: 10.1016/j.nlm.2015.07.005

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  37 in total

1.  Local gene knockdown in the brain using viral-mediated RNA interference.

Authors:  Jonathan D Hommel; Robert M Sears; Dan Georgescu; Diana L Simmons; Ralph J DiLeone
Journal:  Nat Med       Date:  2003-11-23       Impact factor: 53.440

2.  Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

Authors:  Ryan L Boudreau; Inês Martins; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

3.  An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene.

Authors:  E Myslinski; J C Amé; A Krol; P Carbon
Journal:  Nucleic Acids Res       Date:  2001-06-15       Impact factor: 16.971

4.  shRNA-induced saturation of the microRNA pathway in the rat brain.

Authors:  M A van Gestel; S van Erp; L E Sanders; M A D Brans; M C M Luijendijk; M Merkestein; R J Pasterkamp; R A H Adan
Journal:  Gene Ther       Date:  2014-01-02       Impact factor: 5.250

Review 5.  Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century.

Authors:  Mario R Capecchi
Journal:  Nat Rev Genet       Date:  2005-06       Impact factor: 53.242

6.  Increased expression of the immediate-early gene arc/arg3.1 reduces AMPA receptor-mediated synaptic transmission.

Authors:  Emiliano M Rial Verde; Jane Lee-Osbourne; Paul F Worley; Roberto Malinow; Hollis T Cline
Journal:  Neuron       Date:  2006-11-09       Impact factor: 17.173

7.  Degradation of postsynaptic scaffold GKAP and regulation of dendritic spine morphology by the TRIM3 ubiquitin ligase in rat hippocampal neurons.

Authors:  Albert Y Hung; Clifford C Sung; Ilana L Brito; Morgan Sheng
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

8.  Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet.

Authors:  Matthew C Althage; Eric L Ford; Songyan Wang; Patrick Tso; Kenneth S Polonsky; Burton M Wice
Journal:  J Biol Chem       Date:  2008-04-17       Impact factor: 5.157

9.  Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories.

Authors:  Niels Plath; Ora Ohana; Björn Dammermann; Mick L Errington; Dietmar Schmitz; Christina Gross; Xiaosong Mao; Arne Engelsberg; Claudia Mahlke; Hans Welzl; Ursula Kobalz; Anastasia Stawrakakis; Esperanza Fernandez; Robert Waltereit; Anika Bick-Sander; Eric Therstappen; Sam F Cooke; Veronique Blanquet; Wolfgang Wurst; Benedikt Salmen; Michael R Bösl; Hans-Peter Lipp; Seth G N Grant; Tim V P Bliss; David P Wolfer; Dietmar Kuhl
Journal:  Neuron       Date:  2006-11-09       Impact factor: 17.173

10.  Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala.

Authors:  Roopashri Holehonnur; Jonathan A Luong; Dushyant Chaturvedi; Anthony Ho; Srihari K Lella; Matthew P Hosek; Jonathan E Ploski
Journal:  BMC Neurosci       Date:  2014-02-18       Impact factor: 3.288

View more
  5 in total

1.  The Development of a Viral Mediated CRISPR/Cas9 System with Doxycycline Dependent gRNA Expression for Inducible In vitro and In vivo Genome Editing.

Authors:  Christopher A de Solis; Anthony Ho; Roopashri Holehonnur; Jonathan E Ploski
Journal:  Front Mol Neurosci       Date:  2016-08-18       Impact factor: 5.639

2.  Is Arc mRNA Unique: A Search for mRNAs That Localize to the Distal Dendrites of Dentate Gyrus Granule Cells Following Neural Activity.

Authors:  Christopher A de Solis; Anna A Morales; Matthew P Hosek; Alex C Partin; Jonathan E Ploski
Journal:  Front Mol Neurosci       Date:  2017-10-10       Impact factor: 5.639

Review 3.  RISC-y Business: Limitations of Short Hairpin RNA-Mediated Gene Silencing in the Brain and a Discussion of CRISPR/Cas-Based Alternatives.

Authors:  Kanishk Goel; Jonathan E Ploski
Journal:  Front Mol Neurosci       Date:  2022-07-26       Impact factor: 6.261

4.  The Development of an AAV-Based CRISPR SaCas9 Genome Editing System That Can Be Delivered to Neurons in vivo and Regulated via Doxycycline and Cre-Recombinase.

Authors:  Namrata Kumar; William Stanford; Christopher de Solis; Nigel D Abraham; Trieu-Mi J Dao; Sadiqa Thaseen; Anusha Sairavi; Cuauhtemoc Ulises Gonzalez; Jonathan E Ploski
Journal:  Front Mol Neurosci       Date:  2018-11-13       Impact factor: 5.639

Review 5.  Genetically Engineering the Nervous System with CRISPR-Cas.

Authors:  Alfredo Sandoval; Hajira Elahi; Jonathan E Ploski
Journal:  eNeuro       Date:  2020-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.